RC

Roshantha A. Chandraratna

AB AbbVie: 221 patents #1 of 1,308Top 1%
IT Io Therapeutics: 63 patents #1 of 19Top 6%
DC Dartmouth College: 8 patents #35 of 689Top 6%
JM Johns Hopkins University School Of Medicine: 4 patents #40 of 255Top 20%
The Johns Hopkins University: 2 patents #1,071 of 4,416Top 25%
JM John Hopkins University, School Of Medicine: 1 patents #7 of 55Top 15%
TT The University Of Texas: 1 patents #15 of 46Top 35%
CC City Of Hope National Medical Center: 1 patents #2 of 13Top 20%
📍 San Juan Capistrano, CA: #2 of 406 inventorsTop 1%
🗺 California: #245 of 386,348 inventorsTop 1%
Overall (All Time): #1,365 of 4,157,543Top 1%
294
Patents All Time

Issued Patents All Time

Showing 51–75 of 294 patents

Patent #TitleCo-InventorsDate
10213401 Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy Martin E. Sanders 2019-02-26
10201512 Autoimmune disorder treatment using RXR agonists Ethan Dmitrovsky, Elizabeth Nowak, Randolph J. Noelle 2019-02-12
10188618 Treatment of cancer with specific RXR agonists 2019-01-29
10123982 Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy Martin E. Sanders 2018-11-13
10092535 Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones Martin E. Sanders 2018-10-09
10039731 Treatment of cancer with specific RXR agonists 2018-08-07
10034845 Autoimmune disorder treatment using RXR agonists Ethan Dmitrovsky, Elizabeth Nowak, Randolph J. Noelle 2018-07-31
10004709 Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy Martin E. Sanders 2018-06-26
10004708 Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy Martin E. Sanders 2018-06-26
9907768 Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy Martin E. Sanders 2018-03-06
9877941 Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones Martin E. Sanders 2018-01-30
9717702 Treatment of cancer with specific RXR agonists 2017-08-01
9655872 Treatment of cancer with specific RXR agonists 2017-05-23
9308186 Treatment of cancer with specific RXR agonists 2016-04-12
9271946 Use of a RAR antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects Yang-Dar Yuan 2016-03-01
8101662 Treatment of cancer with specific RXR agonists 2012-01-24
7638648 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li +5 more 2009-12-29
7476673 Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors Kwok Yin Tsang, Santosh C. Sinha, Xiaoxia Liu, Smita S. Bhat 2009-01-13
7468391 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B Jayasree Vasudevan, Rong Yang, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang +5 more 2008-12-23
7432388 Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity Kwok Yin Tsang, Santosh C. Sinha, Xiaoxia Liu, Smita S. Bhat 2008-10-07
7351737 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Yang-Dar Yuan 2008-04-01
7253319 Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity Kwok Yin Tsang, Santosh C. Sinha, Xiaoxia Liu, Smita S. Bhat 2007-08-07
7226951 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li +5 more 2007-06-05
7166726 Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity Vidyasagar Vuligonda, Alan T. Johnson 2007-01-23
7105566 Methods of treatment during vascular procedures Yang-Dar Yuan, Tuong P. Dang, Sheng Z. Loh 2006-09-12